Document Server@UHasselt >
Research publications >
Please use this identifier to cite or link to this item:
|Title: ||The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience|
|Authors: ||Bielen, Rob|
Van Vlierberghe, H.
Mulkay, J. -P.
de Galocsy, C.
Van Overbeke, L.
Van Steenkiste, C.
|Issue Date: ||2017|
|Citation: ||JOURNAL OF VIRAL HEPATITIS, 24(11), p. 976-981|
|Abstract: ||Recently, concerns were raised of high rates of HCC recurrence in patients treated with direct-acting antivirals (DAA) for hepatitis C infection. We investigated the HCC occurrence and recurrence rates within 6 months after treatment with DAA with or without pegylated interferon (PEG-IFN) in real life. This is a retrospective, multicenter cohort trial, executed in 15 hospitals distributed across Belgium. Populations were matched based on fibrosis score (Metavir F3-F4). Patients with a Child-Pugh score >= B were excluded. In total, 567 patients were included, of whom 77 were treated with PEG-IFN+DAA between 2008 and 2013 and 490 with DAA without PEG-IFN between 2013 and 2015. Patients treated with PEG-IFN+DAA (53 +/- 9y) were younger than patients treated with DAA without PEG-IFN (59 +/- 12y) (P=. 001). 47% of patients treated with PEG-IFN+DAA were in the F4 stage vs 67% of patients treated with DAA without PEG-IFN (P=. 001). Screening was inadequate in 20% of both patient groups (P=. 664). The early occurrence rate of HCC was 1.7% and 1.1% in patients treated with DAA with and without PEG-IFN, respectively (P=. 540). The early recurrence rate was 0% in patients treated with PEG-IFN+DAA and 15.0% in patients treated with DAA without PEG-IFN (P=. 857). There is no difference in early occurrence of new HCC between patients treated with DAA with and without PEG-IFN. We did observe a high early recurrence rate of HCC in patients treated with DAA without PEG-IFN. However, these patients were at baseline more at risk for HCC. Finally, in 20%, screening for HCC was inadequate.|
|Notes: ||[Bielen, R.; Wuyckens, K.; Robaeys, G.] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium. [Bielen, R.; Wuyckens, K.; Robaeys, G.] Ziekenhuis Oost Limburg, Dept Gastroenterol & Hepatol, Genk, Belgium. [Moreno, C.] Erasme Univ Hosp, Dept Gastroenterol & Hepatopancreatol, Brussels, Belgium. [Van Vlierberghe, H.; Van Steenkiste, C.] Univ Hosp Gent, Dept Hepatol & Gastroenterol, Ghent, Belgium. [Bourgeois, S.] ZNA Stuivenberg, Dept Gastroenterol & Hepatol, Antwerp, Belgium. [Mulkay, J. -P.] Hop St Pierre & Erasme, Dept Gastroenterol & Hepatol, Brussels, Belgium. [Vanwolleghem, T.; Verlinden, W.] Antwerp Univ Hosp, Dept Gastroenterol & Hepatol, Edegem, Belgium. [Brixco, C.] CHR Citadelle, Dept Gastroenterol & Digest Oncol, Liege, Belgium. [Decaestecker, J.] AZ Delta, Dept Gastroenterol & Digest Oncol, Roeselare, Belgium. [Decaestecker, J.; Janssens, F.; D'Heygere, F.; Cool, M.; Nevens, F.; Robaeys, G.] Univ Hosp KU Leuven, Dept Gastroenterol & Digest Oncol, Leuven, Belgium. [de Galocsy, C.] Hop HIS Bracops, Dept Gastroenterol & Digest Oncol, Brussels, Belgium. [Janssens, F.] Jessa Hosp, Dept Gastroenterol & Digest Oncol, Hasselt, Belgium. [Van Overbeke, L.] AZ Sint Maarten, Dept Gastroenterol & Digest Oncol, Mechelen, Belgium. [Van Steenkiste, C.] AZ Maria Middelares, Dept Gastroenterol & Digest Oncol, Ghent, Belgium. [D'Heygere, F.] AZ Groeninge, Dept Gastroenterol & Digest Oncol, Kortrijk, Belgium. [Cool, M.] AZ Damiaan, Dept Gastroenterol & Digest Oncol, Oostende, Belgium.|
|ISI #: ||000412859300008|
|Type: ||Journal Contribution|
|Appears in Collections: ||Research publications|
Files in This Item:
|Published version||341.06 kB||Adobe PDF|
|Peer-reviewed author version||157.68 kB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.